TY - JOUR AU - Monami, M. AU - Nardini, C. AU - Mannucci, E. PY - 2014 DA - 2014// TI - Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials JO - Diabetes Obes Metab VL - 16 UR - https://doi.org/10.1111/dom.12244 DO - 10.1111/dom.12244 ID - Monami2014 ER - TY - JOUR AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Mattheus, M. AU - Devins, T. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. PY - 2015 DA - 2015// TI - Inzucchi SE; EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504720 DO - 10.1056/NEJMoa1504720 ID - Zinman2015 ER - TY - JOUR AU - Neal, B. AU - Perkovic, V. AU - Mahaffey, K. W. AU - Zeeuw, D. AU - Fulcher, G. AU - Erondu, N. AU - Shaw, W. AU - Law, G. AU - Desai, M. AU - Matthews, D. R. PY - 2017 DA - 2017// TI - Canagliflozin and cardiovascular and renal events in type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1611925 DO - 10.1056/NEJMoa1611925 ID - Neal2017 ER - TY - JOUR AU - Okamura, T. AU - Kokubo, Y. AU - Watanabe, M. AU - Higashiyama, A. AU - Miyamoto, Y. AU - Yoshimasa, Y. AU - Okayama, A. PY - 2009 DA - 2009// TI - Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study JO - Atherosclerosis VL - 203 UR - https://doi.org/10.1016/j.atherosclerosis.2008.07.020 DO - 10.1016/j.atherosclerosis.2008.07.020 ID - Okamura2009 ER - TY - JOUR AU - Pekkanen, J. AU - Linn, S. AU - Heiss, G. AU - Suchindran, C. M. AU - Leon, A. AU - Rifkind, B. M. AU - Tyroler, H. A. PY - 1990 DA - 1990// TI - Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease JO - N Engl J Med VL - 322 UR - https://doi.org/10.1056/NEJM199006143222403 DO - 10.1056/NEJM199006143222403 ID - Pekkanen1990 ER - TY - JOUR PY - 2019 DA - 2019// TI - 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019 JO - Diabetes Care VL - 42 UR - https://doi.org/10.2337/dc19-S009 DO - 10.2337/dc19-S009 ID - ref6 ER - TY - JOUR AU - Kaku, K. AU - Kiyosue, A. AU - Inoue, S. AU - Ueda, N. AU - Tokudome, T. AU - Yang, J. AU - Langkilde, A. M. PY - 2014 DA - 2014// TI - Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise JO - Diabetes Obes Metab VL - 16 UR - https://doi.org/10.1111/dom.12325 DO - 10.1111/dom.12325 ID - Kaku2014 ER - TY - JOUR AU - Yoon, K. H. AU - Lee, J. H. AU - Kim, J. W. AU - Cho, J. H. AU - Choi, Y. H. AU - Ko, S. H. AU - Zimmet, P. AU - Son, H. Y. PY - 2006 DA - 2006// TI - Epidemic obesity and type 2 diabetes in Asia JO - Lancet VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69703-1 DO - 10.1016/S0140-6736(06)69703-1 ID - Yoon2006 ER - TY - JOUR PY - 2004 DA - 2004// TI - Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies JO - Lancet VL - 363 UR - https://doi.org/10.1016/S0140-6736(03)15268-3 DO - 10.1016/S0140-6736(03)15268-3 ID - ref9 ER - TY - JOUR AU - Zhang, C. AU - Gao, F. AU - Luo, H. AU - Zhang, C. T. AU - Zhang, R. PY - 2015 DA - 2015// TI - Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity JO - Cardiovasc Diabetol VL - 14 UR - https://doi.org/10.1186/s12933-015-0240-1 DO - 10.1186/s12933-015-0240-1 ID - Zhang2015 ER - TY - JOUR AU - Cai, X. AU - Gao, X. AU - Yang, W. AU - Chen, Y. AU - Zhang, S. AU - Zhou, L. AU - Han, X. AU - Ji, L. PY - 2018 DA - 2018// TI - No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: a meta-analysis JO - J Diab Investig VL - 9 UR - https://doi.org/10.1111/jdi.12760 DO - 10.1111/jdi.12760 ID - Cai2018 ER - TY - JOUR AU - Jadad, A. R. AU - Moore, R. A. AU - Carroll, D. AU - Jenkinson, C. AU - Reynolds, D. J. AU - Gavaghan, D. J. AU - McQuay, H. J. PY - 1996 DA - 1996// TI - Assessing the quality of reports of randomized clinical trials: is blinding necessary? JO - Control Clin Trials VL - 17 UR - https://doi.org/10.1016/0197-2456(95)00134-4 DO - 10.1016/0197-2456(95)00134-4 ID - Jadad1996 ER - TY - BOOK PY - 2011 DA - 2011// TI - Cochrane handbook for systematic reviews of interventions, Version 5.1.0 [updated March 2011]: The Cochrane Collaboration ID - ref13 ER - TY - JOUR AU - DerSimonian, R. AU - Laird, N. PY - 1986 DA - 1986// TI - Meta-analysis in clinical trials JO - Control Clin Trials VL - 7 UR - https://doi.org/10.1016/0197-2456(86)90046-2 DO - 10.1016/0197-2456(86)90046-2 ID - DerSimonian1986 ER - TY - JOUR AU - Egger, M. AU - Davey Smith, G. AU - Schneider, M. AU - Minder, C. PY - 1997 DA - 1997// TI - Bias in meta-analysis detected by a simple, graphical test JO - BMJ VL - 315 UR - https://doi.org/10.1136/bmj.315.7109.629 DO - 10.1136/bmj.315.7109.629 ID - Egger1997 ER - TY - JOUR AU - Ji, L. AU - Ma, J. AU - Li, H. AU - Mansfield, T. A. AU - T'joen, C. L. AU - Iqbal, N. AU - Ptaszynska, A. AU - List, J. F. PY - 2014 DA - 2014// TI - Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study JO - Clin Ther VL - 36 UR - https://doi.org/10.1016/j.clinthera.2013.11.002 DO - 10.1016/j.clinthera.2013.11.002 ID - Ji2014 ER - TY - JOUR AU - Kadowaki, T. AU - Haneda, M. AU - Inagaki, N. AU - Terauchi, Y. AU - Taniguchi, A. AU - Koiwai, K. AU - Rattunde, H. AU - Woerle, H. J. AU - Broedl, U. C. PY - 2014 DA - 2014// TI - Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial JO - Adv Ther VL - 31 UR - https://doi.org/10.1007/s12325-014-0126-8 DO - 10.1007/s12325-014-0126-8 ID - Kadowaki2014 ER - TY - JOUR AU - Kashiwagi, A. AU - Takahashi, H. AU - Ishikawa, H. AU - Yoshida, S. AU - Kazuta, K. AU - Utsuno, A. AU - Ueyama, E. PY - 2015 DA - 2015// TI - A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study JO - Diabetes Obes Metab VL - 17 UR - https://doi.org/10.1111/dom.12403 DO - 10.1111/dom.12403 ID - Kashiwagi2015 ER - TY - JOUR AU - Lu, C. H. AU - Min, K. W. AU - Chuang, L. M. AU - Kokubo, S. AU - Yoshida, S. AU - Cha, B. S. PY - 2016 DA - 2016// TI - Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial JO - J Diab Investig VL - 7 UR - https://doi.org/10.1111/jdi.12422 DO - 10.1111/jdi.12422 ID - Lu2016 ER - TY - JOUR AU - Kashiwagi, A. AU - Kazuta, K. AU - Goto, K. AU - Yoshida, S. AU - Ueyama, E. AU - Utsuno, A. PY - 2015 DA - 2015// TI - Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study JO - Diabetes Obes Metab VL - 17 UR - https://doi.org/10.1111/dom.12331 DO - 10.1111/dom.12331 ID - Kashiwagi2015 ER - TY - JOUR AU - Kashiwagi, A. AU - Akiyama, N. AU - Shiga, T. AU - Kazuta, K. AU - Utsuno, A. AU - Yoshida, S. AU - Ueyama, E. PY - 2015 DA - 2015// TI - Efficacy and safety of Ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study JO - Diabetol Int VL - 6 UR - https://doi.org/10.1007/s13340-014-0184-9 DO - 10.1007/s13340-014-0184-9 ID - Kashiwagi2015 ER - TY - JOUR AU - Kashiwagi, A. AU - Shiga, T. AU - Akiyama, N. AU - Akiyama, N. AU - Kazuta, K. AU - Utsuno, A. AU - Yoshida, S. AU - Ueyama, E. PY - 2015 DA - 2015// TI - Efficacy and safety of Ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study) JO - Diabetol Int VL - 6 UR - https://doi.org/10.1007/s13340-014-0182-y DO - 10.1007/s13340-014-0182-y ID - Kashiwagi2015 ER - TY - JOUR AU - Kashiwagi, A. AU - Kazuta, K. AU - Takinami, Y. AU - Yoshida, S. AU - Utsuno, A. AU - Nagase, I. PY - 2015 DA - 2015// TI - Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study JO - Diabetol Int VL - 6 UR - https://doi.org/10.1007/s13340-014-0164-0 DO - 10.1007/s13340-014-0164-0 ID - Kashiwagi2015 ER - TY - JOUR AU - Haneda, M. AU - Seino, Y. AU - Inagaki, N. AU - Kaku, K. AU - Sasaki, T. AU - Fukatsu, A. AU - Kakiuchi, H. AU - Sato, Y. AU - Sakai, S. AU - Samukawa, Y. PY - 2016 DA - 2016// TI - Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus JO - Clin Ther VL - 38 UR - https://doi.org/10.1016/j.clinthera.2015.10.025 DO - 10.1016/j.clinthera.2015.10.025 ID - Haneda2016 ER - TY - JOUR AU - Seino, Y. AU - Sasaki, T. AU - Fukatsu, A. AU - Ubukata, M. AU - Sakai, S. AU - Samukawa, Y. PY - 2014 DA - 2014// TI - Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study JO - Curr Med Res Opin VL - 30 UR - https://doi.org/10.1185/03007995.2014.912983 DO - 10.1185/03007995.2014.912983 ID - Seino2014 ER - TY - JOUR AU - Seino, Y. AU - Sasaki, T. AU - Fukatsu, A. AU - Ubukata, M. AU - Sakai, S. AU - Samukawa, Y. PY - 2014 DA - 2014// TI - Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study JO - Curr Med Res Opin VL - 30 UR - https://doi.org/10.1185/03007995.2014.909390 DO - 10.1185/03007995.2014.909390 ID - Seino2014 ER - TY - JOUR AU - Seino, Y. AU - Sasaki, T. AU - Fukatsu, A. AU - Sakai, S. AU - Samukawa, Y. PY - 2014 DA - 2014// TI - Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study JO - Curr Med Res Opin VL - 30 UR - https://doi.org/10.1185/03007995.2014.901943 DO - 10.1185/03007995.2014.901943 ID - Seino2014 ER - TY - JOUR AU - Inagaki, N. AU - Harashima, S. AU - Maruyama, N. AU - Kawaguchi, Y. AU - Goda, M. AU - Iijima, H. PY - 2016 DA - 2016// TI - Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus JO - Cardiovasc Diabetol VL - 15 UR - https://doi.org/10.1186/s12933-016-0407-4 DO - 10.1186/s12933-016-0407-4 ID - Inagaki2016 ER - TY - JOUR AU - Ji, L. AU - Han, P. AU - Liu, Y. AU - Yang, G. AU - Dieu Van, N. K. AU - Vijapurkar, U. AU - Qiu, R. AU - Meininger, G. PY - 2015 DA - 2015// TI - Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea JO - Diabetes Obes Metab VL - 17 UR - https://doi.org/10.1111/dom.12385 DO - 10.1111/dom.12385 ID - Ji2015 ER - TY - JOUR AU - Inagaki, N. AU - Kondo, K. AU - Yoshinari, T. AU - Takahashi, N. AU - Susuta, Y. AU - Kuki, H. PY - 2014 DA - 2014// TI - Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study JO - Expert Opin Pharmacother VL - 15 UR - https://doi.org/10.1517/14656566.2014.935764 DO - 10.1517/14656566.2014.935764 ID - Inagaki2014 ER - TY - JOUR AU - Inagaki, N. AU - Kondo, K. AU - Yoshinari, T. AU - Maruyama, N. AU - Susuta, Y. AU - Kuki, H. PY - 2013 DA - 2013// TI - Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study JO - Diabetes Obes Metab VL - 15 UR - https://doi.org/10.1111/dom.12149 DO - 10.1111/dom.12149 ID - Inagaki2013 ER - TY - JOUR AU - Kaku, K. AU - Watada, H. AU - Iwamoto, Y. AU - Utsunomiya, K. AU - Terauchi, Y. AU - Tobe, K. AU - Tanizawa, Y. AU - Araki, E. AU - Ueda, M. AU - Suganami, H. AU - Watanabe, D. PY - 2014 DA - 2014// TI - Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study JO - Cardiovasc Diabetol VL - 13 UR - https://doi.org/10.1186/1475-2840-13-65 DO - 10.1186/1475-2840-13-65 ID - Kaku2014 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - Ann Intern Med VL - 151 UR - https://doi.org/10.7326/0003-4819-151-4-200908180-00135 DO - 10.7326/0003-4819-151-4-200908180-00135 ID - Moher2009 ER - TY - JOUR AU - Barter, P. AU - Gotto, A. M. AU - LaRosa, J. C. AU - Maroni, J. AU - Szarek, M. AU - Grundy, S. M. AU - Kastelein, J. J. AU - Bittner, V. AU - Fruchart, J. C. PY - 2007 DA - 2007// TI - Treating to new targets investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa064278 DO - 10.1056/NEJMoa064278 ID - Barter2007 ER - TY - JOUR AU - Marston, N. A. AU - Giugliano, R. P. AU - Im, K. AU - Silverman, M. G. AU - O'Donoghue, M. L. AU - Wiviott, S. D. AU - Ference, B. A. AU - Sabatine, M. S. PY - 2019 DA - 2019// TI - Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials JO - Circulation VL - 140 UR - https://doi.org/10.1161/CIRCULATIONAHA.119.041998 DO - 10.1161/CIRCULATIONAHA.119.041998 ID - Marston2019 ER - TY - JOUR AU - Kearney, P. M. AU - Blackwell, L. AU - Collins, R. AU - Keech, A. AU - Simes, J. AU - Peto, R. AU - Armitage, J. AU - Baigent, C. PY - 2008 DA - 2008// TI - Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis JO - Lancet VL - 371 UR - https://doi.org/10.1016/S0140-6736(08)60104-X DO - 10.1016/S0140-6736(08)60104-X ID - Kearney2008 ER - TY - JOUR AU - Yale, J. F. AU - Bakris, G. AU - Cariou, B. AU - Yue, D. AU - David-Neto, E. AU - Xi, L. AU - Figueroa, K. AU - Wajs, E. AU - Usiskin, K. AU - Meininger, G. PY - 2013 DA - 2013// TI - Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease JO - Diabetes Obes Metab VL - 15 UR - https://doi.org/10.1111/dom.12090 DO - 10.1111/dom.12090 ID - Yale2013 ER - TY - JOUR AU - Zinman, B. AU - Inzucchi, S. E. AU - Lachin, J. M. AU - Wanner, C. AU - Ferrari, R. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Kempthorne-Rawson, J. AU - Newman, J. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. PY - 2014 DA - 2014// TI - Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) JO - Cardiovasc Diabetol VL - 13 UR - https://doi.org/10.1186/1475-2840-13-102 DO - 10.1186/1475-2840-13-102 ID - Zinman2014 ER - TY - JOUR AU - Bode, B. AU - Stenlöf, K. AU - Harris, S. AU - Sullivan, D. AU - Fung, A. AU - Usiskin, K. AU - Meininger, G. PY - 2015 DA - 2015// TI - Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes JO - Diabetes Obes Metab VL - 17 UR - https://doi.org/10.1111/dom.12428 DO - 10.1111/dom.12428 ID - Bode2015 ER - TY - JOUR AU - Manley, S. E. AU - Stratton, I. M. AU - Cull, C. A. AU - Frighi, V. AU - Eeley, E. A. AU - Matthews, D. R. AU - Holman, R. R. AU - Turner, R. C. AU - Neil, H. A. PY - 2000 DA - 2000// TI - Effects of three months’ diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45) JO - Diabet Med VL - 17 UR - https://doi.org/10.1046/j.1464-5491.2000.00320.x DO - 10.1046/j.1464-5491.2000.00320.x ID - Manley2000 ER - TY - JOUR AU - Halimi, S. AU - Vergès, B. PY - 2014 DA - 2014// TI - Adverse effects and safety of SGLT-2 inhibitors JO - Diabetes Metab VL - 40 UR - https://doi.org/10.1016/S1262-3636(14)72693-X DO - 10.1016/S1262-3636(14)72693-X ID - Halimi2014 ER - TY - JOUR AU - Basu, D. AU - Huggins, L. A. AU - Scerbo, D. AU - Obunike, J. AU - Mullick, A. E. AU - Rothenberg, P. L. AU - Prospero, N. A. AU - Eckel, R. H. AU - Goldberg, I. J. PY - 2018 DA - 2018// TI - Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose Cotransporter 2) inhibition JO - Arterioscler Thromb Vasc Biol VL - 38 UR - https://doi.org/10.1161/ATVBAHA.118.311339 DO - 10.1161/ATVBAHA.118.311339 ID - Basu2018 ER - TY - JOUR AU - Heilbronn, L. K. AU - Noakes, M. AU - Clifton, P. M. PY - 1999 DA - 1999// TI - Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes JO - Diabetes Care VL - 22 UR - https://doi.org/10.2337/diacare.22.6.889 DO - 10.2337/diacare.22.6.889 ID - Heilbronn1999 ER - TY - JOUR AU - Kelley, G. A. AU - Kelley, K. S. PY - 2007 DA - 2007// TI - Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials JO - Public Health VL - 121 UR - https://doi.org/10.1016/j.puhe.2007.02.014 DO - 10.1016/j.puhe.2007.02.014 ID - Kelley2007 ER -